Barclays PLC Boosts Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Barclays PLC lifted its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 345.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 98,663 shares of the company's stock after buying an additional 76,538 shares during the period. Barclays PLC owned approximately 0.26% of Tarsus Pharmaceuticals worth $3,246,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Wellington Management Group LLP boosted its stake in Tarsus Pharmaceuticals by 14.2% in the third quarter. Wellington Management Group LLP now owns 145,347 shares of the company's stock valued at $4,780,000 after acquiring an additional 18,019 shares in the last quarter. Ikarian Capital LLC boosted its position in shares of Tarsus Pharmaceuticals by 28.7% in the 3rd quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company's stock worth $33,886,000 after purchasing an additional 230,000 shares in the last quarter. Verition Fund Management LLC purchased a new position in Tarsus Pharmaceuticals during the 3rd quarter worth $763,000. Vestal Point Capital LP acquired a new position in Tarsus Pharmaceuticals during the 3rd quarter valued at about $7,565,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Tarsus Pharmaceuticals by 10.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,835 shares of the company's stock valued at $1,935,000 after buying an additional 5,709 shares during the last quarter. Institutional investors own 90.01% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Oppenheimer boosted their price target on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an "outperform" rating in a research note on Thursday, November 14th. William Blair raised shares of Tarsus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. Finally, The Goldman Sachs Group raised their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a report on Friday, November 15th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals has a consensus rating of "Buy" and an average target price of $54.20.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS traded down $0.37 during trading hours on Tuesday, reaching $54.04. The stock had a trading volume of 128,793 shares, compared to its average volume of 709,549. Tarsus Pharmaceuticals, Inc. has a 52-week low of $18.99 and a 52-week high of $56.77. The stock has a fifty day moving average of $46.87 and a 200 day moving average of $35.20. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market cap of $2.07 billion, a P/E ratio of -14.18 and a beta of 1.04.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.